AXLRx Book a callCommission

Rare Disease · United States · In-Market

US Gaucher Disease Market Sizing Model

6,000 US Type 1 Gaucher patients size a market near $1.8 billion at ERT pricing. That MedlinePlus-sourced population sits inside a genetic sub-segment where Ashkenazi carrier frequency runs 1 in 12-15, against a general-population disease frequency of just 0.70-1.75 per 100,000.

Assess this report View Sample Models Reviewed by Sneha, Senior Analyst Last updated July 2026
Market United States Stage

Key takeaways

  • 6,000 estimated US Type 1 Gaucher patients · MedlinePlus Genetics, NIH
  • >90% share of all Gaucher disease cases that are Type 1, the population this model sizes
  • 1 in 12–15 Ashkenazi Jewish Gaucher carrier frequency, versus 0.70–1.75 per 100,000 in the general population
  • ~$1.8B ERT-pricing ceiling for the full 6,000-patient population at ~$300,000/year

A single NIH-sourced count of 6,000 US Type 1 Gaucher patients prices out near $1.8 billion at ERT rates, but the same population sits inside an Ashkenazi carrier-frequency band that a sizing model has to reconcile before the number is used in planning.

Gaucher disease type 1 accounts for more than 90 percent of all Gaucher cases, and MedlinePlus Genetics (NIH) estimates roughly 6,000 people live with Type 1 Gaucher disease in the US. That population sits almost entirely inside a genetic sub-segment: general-population disease frequency runs just 0.70 to 1.75 per 100,000, while Ashkenazi Jewish carrier frequency runs roughly 1 in 12 to 15, a concentration that any patient-times-price sizing model must reconcile rather than average away. A model built only on the general-population rate would understate the US Type 1 count; a model built only on the Ashkenazi-specific rate would overstate it outside that founder population.

Applied against approximate annual therapy cost, the 6,000-patient count sizes two ceiling scenarios rather than one blended number. At roughly $300,000 a year for intravenous enzyme replacement therapy, the full population prices out near $1.8 billion; at eliglustat's $310,250 annual WAC for oral substrate reduction therapy, the same population prices out near $1.86 billion. Neither ceiling is the real market, because patients split across enzyme replacement and substrate reduction rather than concentrating on one mechanism, so this model treats the ERT-versus-SRT mix as a scenario input to confirm with the client, not an assumption to bury inside a single point estimate.

Gaucher disease US Type 1 TAM — patient count times price, by mechanism

TAM SIZING
MechanismAnnual PricePatient PopulationTAM Ceiling
IV enzyme replacement therapy (100% scenario)~$300,000/year6,000 (NIH estimate)~$1.8 billion
Oral substrate reduction therapy — eliglustat (100% scenario)$310,250/year WAC6,000 (NIH estimate)~$1.86 billion
Ashkenazi sub-segment cross-check—Carrier frequency 1 in 12–15 vs 0.70–1.75/100,000 general populationDirectional check, not a patient count

Sources: MedlinePlus Genetics (NIH), Gaucher disease; Nalysnyk L et al. Hematology 2016 (PMID 27762169); Balwani M et al. Arch Intern Med 2010 (PMID 20837833); Boston Globe 2014 (eliglustat launch WAC); UnitedHealthcare and Blue Cross Blue Shield Gaucher ERT medical coverage policies (2025-2026).

What this model answers

Every section answers a named commercial question your team is asking, scoped to your asset.

  1. How reliable is the 6,000-patient US Type 1 count, and does the Ashkenazi carrier-frequency sub-segment support or contradict it? • MedlinePlus Genetics (NIH) population estimate • the general-population-versus-Ashkenazi carrier-frequency cross-check • where the two views agree and where they diverge
  2. What is the market worth at ERT pricing versus SRT pricing, and why do the two ceilings differ? • Patient-times-price TAM math at ~$300,000/year ERT and $310,250 eliglustat WAC • the gap between the two ceilings and what drives it
  3. How should a mechanism split between ERT and SRT be built into the model rather than assumed? • A scenario-based ERT-versus-SRT sizing view • the client-alignment questions needed to convert scenario ranges into a single planning number
What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

  1. 1 · The Binding Constraint 2 pp
    • Why the Ashkenazi carrier-frequency sub-segment, not the headline patient count alone, decides whether 6,000 is the right planning number
    • Pressure-tested against the general-population disease frequency of 0.70-1.75 per 100,000 before the rest of the model is built out
  2. 2 · Patient Population Sizing — the NIH Count 2 pp
    • MedlinePlus Genetics (NIH) estimate of roughly 6,000 US Type 1 Gaucher patients
    • Why more than 90% of all Gaucher cases being Type 1 matters for how this count is framed
  3. 3 · Ashkenazi Sub-Segment Cross-Check 2 pp
    • Ashkenazi Jewish carrier frequency of 1 in 12-15 set against general-population disease frequency of 0.70-1.75 per 100,000
    • What the gap between the two rates implies about where the 6,000-patient count concentrates
  4. 4 · TAM Price Ladder — ERT vs SRT Ceilings 2 pp
    • Patient-times-price math at approximately $300,000 a year for IV enzyme replacement therapy
    • The same population priced at eliglustat's $310,250 annual WAC for oral substrate reduction therapy
  5. 5 · Mechanism-Split Scenario View 3 pp
    • Illustrative ERT-versus-SRT treatment-mix scenarios, not a single asserted split
    • How the blended TAM moves as the mechanism mix shifts
  6. 6 · Sensitivity Analysis 2 pp
    • Patient count ranked against price and mechanism mix as the assumptions most likely to move the total
    • Scenario ranges tied to each input
  7. 7 · Editable Excel Model —
    • The full triangulated model, re-runnable with your own assumptions
  8. 8 · Client Alignment Questions 2 pp
    • The open sizing questions your team must close before this number is used in planning

Appendix and source ledger included · 45-minute analyst readout included with delivery

Custom model delivered in 72 hours.

Assess this report

Included with every brief

PDF
PDF Brief
Market Sizing Brief — Complete Edition
PDF methodology brief accompanying the market sizing model: NIH patient count, Ashkenazi sub-segment cross-check, and ERT-versus-SRT TAM scenarios for Gaucher disease US.
XLS
Excel Model
Market Sizing Model — Excel
6-sheet editable model: Cover, Patient Population, Ashkenazi Cross-Check, TAM Price Ladder, Mechanism-Split Scenarios, Sensitivity.

Get Started

Commission this model

AXLRx delivers rare disease market sizing models built for forecasting and strategy teams sizing the US Gaucher Type 1 opportunity. Custom model in 72 hours.

  1. 1. Submit your requestSpecify your indication, market, and mechanism scope.
  2. 2. Scoping callAXLRx analyst confirms sizing methods and treatment-mix assumptions before building.
  3. 3. DeliveryResearch-verified sizing model in 72 hours with optional analyst readout.
Assess this report View sample models

How AXLRx builds this model

Prepared by MoatRx analysts on the AXLRx commercial consulting engine.

Every AXLRx market sizing model triangulates at least two independent methods, direct population estimates and epidemiology-based sub-segment cross-checks, before pricing out a patient population. This is explicitly a sizing model (static patient count and TAM math), distinct from a Pricing Strategy or Launch Readiness model.

Gaucher disease US sizing sources: MedlinePlus Genetics (NIH) for the Type 1 patient count, Nalysnyk et al. Hematology 2016 (PMID 27762169) for the Type 1 case share, Balwani et al. Arch Intern Med 2010 (PMID 20837833) for Ashkenazi Jewish carrier frequency, and Boston Globe 2014 reporting plus payer coverage policy for ERT and eliglustat pricing.

  • US Type 1 patient count (6,000) verified against MedlinePlus Genetics (NIH)
  • Type 1 case share (>90%) verified against Nalysnyk et al. Hematology 2016 (PMID 27762169)
  • Ashkenazi Jewish carrier frequency (1 in 12–15) verified against Balwani et al. Arch Intern Med 2010 (PMID 20837833)
  • ERT annual cost (~$300,000) and eliglustat launch WAC ($310,250) verified against payer coverage policy and Boston Globe 2014 reporting

Frequently asked questions

Methodology Why does this model use 6,000 as the US Type 1 Gaucher patient count instead of deriving it from general-population prevalence?

MedlinePlus Genetics (NIH) publishes a direct estimate of roughly 6,000 US Type 1 patients. General-population disease frequency (0.70 to 1.75 per 100,000) is used as a sub-segment cross-check against the Ashkenazi Jewish carrier-frequency band (1 in 12 to 15), not as the primary count, since Gaucher disease concentrates so heavily in that founder population.

Pricing Why does the model show two TAM ceilings instead of one number?

Intravenous enzyme replacement therapy costs approximately $300,000 per patient per year, while oral eliglustat launched at a $310,250 annual WAC. Because the 6,000-patient population splits across both mechanisms rather than concentrating on one, this model prices both ceilings and treats the actual ERT-versus-SRT mix as a scenario input to confirm with the client.

Deliverables What formats are included with every model?

Every commissioned Market Sizing Model includes an editable Excel model and a PDF methodology brief, no PowerPoint deck, since a sizing model is built to be worked in directly rather than presented from. An optional 45-minute analyst readout call is included.